Health ❯ Clinical Trials

Phase 2 Trials

Male Birth Control Cancer Treatments Hair Growth Studies Efficacy and Safety Patient Dropout Rates Randomized Controlled Trials Drug Efficacy Metabolic Dysfunction Medication Efficacy VLA15-221 Study Drug Development mRNA Technology Weight Loss Drugs

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Phase 3 trials are set to begin this quarter following 48-week topline data showing large placebo-adjusted weight loss.

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion